Invicta Diagnostic's IPO debuted strongly on December 8, listing at ₹100, a 17.65% premium over its issue price of ₹85. The ...

The monkeypox outbreak is pushing demand for innovative In Vitro Diagnostic solutions. Key market opportunities include rapid diagnostics and genomics advancements, driven by global testing ...

The assay detects aggressive prostate tumors in men on active surveillance for low-risk cancer, potentially helping them ...

The field of cancer immunology has experienced remarkable advancements in diagnostic capabilities, largely due to the integration of multispectral and hyperspectral imaging technologies. These imaging ...

Invicta Diagnostic was trading at Rs 95 on the NSE, a 11.76% premium to the issue price of Rs 85. Invicta Diagnostic's IPO was subscribed 4.05 times. The issue opened for bidding on 1 December 2025 ...

Stock rise in today's trade. PC Jeweller shares rose on Monday after the company announced a new collaboration aimed at ...

Shares of Invicta Diagnostic listed at Rs 100 per share on the Emerge platform of the National Stock Exchange (NSE). The Rs 28.12 crore issue had a price band of Rs 80-85 per share.

Invicta Diagnostic is set to debut on the NSE SME platform on December 8, following a successful IPO that raised 28.12 crore.